TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
TC BioPharm (NASDAQ: TCBP) has announced plans to initiate Proof of Concept preclinical studies for its lead therapeutic TCB 008 in the treatment of monkeypox. TCB008 is an allogeneic unmodified cell therapy composed of activated and expanded gamma delta T (GDT) cells. The company aims to partner with a leading Infectious Disease Center or University to rapidly advance these studies.
CEO Bryan Kobel highlighted the potential of gamma delta t-cells in mounting a successful immune response against viral infections. TCBP sees this as an opportunity to expand the therapeutic applications of TCB008, particularly in rapid response to aggressive viral infections. The company believes its frozen/thawed product could potentially prevent death, reduce extended viral infection, and help contain the spread of infectious diseases like monkeypox.
TC BioPharm (NASDAQ: TCBP) ha annunciato piani per avviare studi preclinici di Proof of Concept per il suo principale trattamento TCB 008 nella cura del vaiolo delle scimmie. TCB008 è una terapia cellulare allogenica non modificata composta da cellule T gamma delta (GDT) attivate ed espanse. L'azienda punta a collaborare con un Centro di Malattie Infettive o Università di primo piano per avanzare rapidamente questi studi.
Il CEO Bryan Kobel ha sottolineato il potenziale delle cellule T gamma delta nel montare una risposta immunitaria efficace contro le infezioni virali. TCBP vede questa come un'opportunità per espandere le applicazioni terapeutiche di TCB008, in particolare in risposta rapida a infezioni virali aggressive. L'azienda crede che il suo prodotto congelato/riscaldato possa potenzialmente prevenire la morte, ridurre l'infezione virale prolungata e aiutare a contenere la diffusione di malattie infettive come il vaiolo delle scimmie.
TC BioPharm (NASDAQ: TCBP) ha anunciado planes para iniciar estudios preclínicos de Proof of Concept para su terapéutica principal TCB 008 en el tratamiento de la viruela símica. TCB008 es una terapia celular alogénica no modificada compuesta por células T gamma delta (GDT) activadas y ampliadas. La empresa tiene como objetivo asociarse con un Centro de Enfermedades Infecciosas o Universidad de prestigio para avanzar rápidamente en estos estudios.
El CEO Bryan Kobel destacó el potencial de las células T gamma delta para montar una respuesta inmune exitosa contra infecciones virales. TCBP ve esto como una oportunidad para expandir las aplicaciones terapéuticas de TCB008, especialmente en respuesta rápida a infecciones virales agresivas. La empresa cree que su producto congelado/descongelado podría prevenir la muerte, reducir la infección viral prolongada y ayudar a contener la propagación de enfermedades infecciosas como la viruela símica.
TC BioPharm (NASDAQ: TCBP)는 원숭이두창 치료를 위한 주요 치료제 TCB 008의 개념 증명 전임상 연구를 시작할 계획을 발표했습니다. TCB008은 활성화되고 확장된 감마 델타 T (GDT) 세포로 구성된 비변형 공여 세포 요법입니다. 회사는 이러한 연구를 신속하게 진행하기 위해 주요 전염병 센터 또는 대학과 협력할 계획입니다.
CEO 브라이언 코벨은 감마 델타 T 세포가 바이러스 감염에 대해 성공적인 면역 반응을 유도할 수 있는 잠재력을 강조했습니다. TCBP는 TCB008의 치료적 응용 프로그램을 확장할 수 있는 기회로 보고 있으며, 특히 공격적인 바이러스 감염에 대한 신속한 대응을 목표로 하고 있습니다. 회사는 자신의 냉동/해동 제품이 사망을 예방하고, 지속적인 바이러스 감염을 줄이며, 원숭이두창과 같은 전염병 확산을 억제하는 데 도움이 될 수 있다고 믿고 있습니다.
TC BioPharm (NASDAQ: TCBP) a annoncé des plans pour initier des études précliniques de Proof of Concept pour son principal traitement TCB 008 dans le cadre du traitement de la variole simienne. TCB008 est une thérapie cellulaire allogénique non modifiée composée de cellules T gamma delta (GDT) activées et expansées. L'entreprise vise à s'associer à un Centre des Maladies Infectieuses ou une Université de premier plan pour faire avancer rapidement ces études.
Le PDG Bryan Kobel a souligné le potentiel des cellules T gamma delta à déclencher une réponse immunitaire efficace contre les infections virales. TCBP considère cela comme une opportunité d'élargir les applications thérapeutiques de TCB008, en particulier en réponse rapide aux infections virales agressives. L'entreprise croit que son produit congelé/décongelé pourrait potentiellement prévenir la mort, réduire l'infection virale prolongée et aider à contenir la propagation de maladies infectieuses telles que la variole simienne.
TC BioPharm (NASDAQ: TCBP) hat Pläne angekündigt, Proof of Concept präklinische Studien für sein Haupttherapeutikum TCB 008 zur Behandlung von Affenpocken zu initiieren. TCB008 ist eine allogene nicht modifizierte Zelltherapie, die aus aktivierten und expandierten Gamma-Delta-T (GDT) Zellen besteht. Das Unternehmen beabsichtigt, mit einem führenden Zentrum für Infektionskrankheiten oder einer Universität zusammenzuarbeiten, um diese Studien schnell voranzutreiben.
CEO Bryan Kobel hob das Potenzial der Gamma-Delta-T-Zellen hervor, eine erfolgreiche Immunantwort gegen Virusinfektionen zu erzeugen. TCBP sieht hierin eine Möglichkeit, die therapeutischen Anwendungen von TCB008 zu erweitern, insbesondere als schnelle Reaktion auf aggressive Virusinfektionen. Das Unternehmen glaubt, dass sein gefrorenes/aufgetautes Produkt möglicherweise den Tod verhindern, verlängerte Virusinfektionen verringern und zur Eindämmung der Verbreitung von Infektionskrankheiten wie Affenpocken beitragen kann.
- Expansion of TCB008's potential applications to include treatment of monkeypox
- Planned partnership with leading Infectious Disease Center or University for rapid study advancement
- Potential for TCB008 to prevent death, reduce viral infection duration, and contain disease spread
- Studies are still in early preclinical stage
- No guaranteed success or timeline for development provided
- Potential regulatory hurdles for new application of existing therapy
TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) cells which the company expects will have applications in treating the global health emergency. Due to the highly infectious nature of monkeypox, TCBP expects to partner with a leading Infectious Disease Center or University associated with a similar organization to rapidly advance the Proof-of-Concept and pre-clinical studies.
"There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells," commented CEO Bryan Kobel. "We continue to look at avenues to expand the therapeutic applications for TCB008 and moving into rapid response for aggressive viral infections is an arena we believe our therapeutic can be immediately impactful. The ability to deliver a frozen/thawed product to these patients to prevent not just the death or extended viral infection in these patients, but also potentially slow the spread of the infectious disease and contain the issue from becoming a global pandemic, would represent a massive global opportunity and market size. We look forward to updating investors as we further this program."
Mpox (monkeypox) is a viral illness caused by a species of the genus Orthopoxvirus. Two different clades exist: clade I and clade II. Common symptoms of the virus are a skin rash or mucosal lesions which can last 2–4 weeks accompanied by fever, headache, muscle aches, back pain, low energy, and swollen lymph nodes. The disease can be transmitted to humans through physical contact with someone who is infectious, with contaminated materials, or with infected animals. In 2022–2023 a global outbreak of mpox was caused by a strain known as clade IIb.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-intends-to-launch-preclinical-studies-for-treatment-of-monkey-pox-302239997.html
SOURCE TC BioPharm
FAQ
What is TC BioPharm's plan for treating monkeypox?
How does TCB008 work against viral infections like monkeypox?
What are the potential benefits of TC BioPharm's monkeypox treatment?
When will TC BioPharm (TCBP) start its monkeypox treatment studies?
